Biosensor‐Based Microfluidic Platforms for Rapid Clinical Detection of Pathogenic Bacteria DOI Open Access

Ying Hou,

Zhen Liu, Haina Huang

et al.

Advanced Functional Materials, Journal Year: 2024, Volume and Issue: unknown

Published: Nov. 20, 2024

Abstract Pathogenic bacteria are commonly found in food, water, and soil, posing significant public health challenges globally. Therefore, early, rapid, highly sensitive strategies for monitoring the bacterial proliferation crucial ensuring health, medical diagnosis, food safety. Compared to traditional techniques, microfluidic platforms provide powerful detective tools characterized by high integration, throughput, ease of operation, low reagent consumption, sensitivity. Driven substantial commercial demand, research development microfluidic‐based rapid detection methods technologies has progressed significantly derived interdisciplinary integration multiple disciplines. In this review, progress clinical pathogenic with biosensors, including devices point‐of‐care (POC) testing, is summarized. Strategies detection, containing their advantages disadvantages discussed detail. Advanced capturing detecting bacteria, such as microchannels, microarrays, digital microfluidics (DMF) paper‐based platforms, highlighted. The accomplishments shortcomings these also Additionally, case studies biosensor‑based used diseases caused imbalances listed. Finally, possible perspectives further effective proposed.

Language: Английский

Lung microbiome: new insights into the pathogenesis of respiratory diseases DOI Creative Commons
Ruomeng Li, Jing Li, Xikun Zhou

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Jan. 17, 2024

The lungs were long thought to be sterile until technical advances uncovered the presence of lung microbial community. microbiome healthy is mainly derived from upper respiratory tract (URT) but also has its own characteristic flora. selection mechanisms in lung, including clearance by coughing, pulmonary macrophages, oscillation cilia, and bacterial inhibition alveolar surfactant, keep transient mobile, which different other organs. bacteriome been intensively studied recently, relatively little research focused on mycobiome virome. This up-to-date review retrospectively summarizes microbiome's history, composition, function. We focus interaction with oropharynx gut emphasize role it plays innate adaptive immune responses. More importantly, we multiple diseases, asthma, chronic obstructive disease (COPD), fibrosis, bronchiectasis, pneumonia. impact coronavirus 2019 (COVID-19) cancer comprehensively studied. Furthermore, summarizing therapeutic potential diseases examining shortcomings field, propose an outlook direction research.

Language: Английский

Citations

112
The airway microbiome mediates the interaction between environmental exposure and respiratory health in humans DOI
Lifeng Lin, Xinzhu Yi, Haiyue Liu

et al.

Nature Medicine, Journal Year: 2023, Volume and Issue: 29(7), P. 1750 - 1759

Published: June 22, 2023

Language: Английский

Citations

45
Airway dysbiosis accelerates lung function decline in chronic obstructive pulmonary disease DOI Creative Commons
Weijie Liang, Yuqiong Yang, Shenhai Gong

et al.

Cell Host & Microbe, Journal Year: 2023, Volume and Issue: 31(6), P. 1054 - 1070.e9

Published: May 18, 2023

Language: Английский

Citations

44
Airway ‘Resistotypes’ and Clinical Outcomes in Bronchiectasis DOI
Micheál Mac Aogáin, Fransiskus Xaverius Ivan, Tavleen Kaur Jaggi

et al.

American Journal of Respiratory and Critical Care Medicine, Journal Year: 2024, Volume and Issue: 210(1), P. 47 - 62

Published: Jan. 25, 2024

Chronic infection and inflammation shapes the airway microbiome in bronchiectasis. Utilizing whole-genome shotgun metagenomics to analyze resistome provides insight into interplay between microbes, resistance genes, clinical outcomes.

Language: Английский

Citations

14
Rethinking bronchiectasis as an inflammatory disease DOI

Merete Long,

Sanjay H. Chotirmall, Michal Shteinberg

et al.

The Lancet Respiratory Medicine, Journal Year: 2024, Volume and Issue: 12(11), P. 901 - 914

Published: July 3, 2024

Language: Английский

Citations

12
Dual-function regulator MexL as a target to control phenazines production and pathogenesis of Pseudomonas aeruginosa DOI Creative Commons

Zhaoxiao Yu,

Zhikun Wu, Dejian Liu

et al.

Nature Communications, Journal Year: 2025, Volume and Issue: 16(1)

Published: Feb. 26, 2025

Antibiotic resistance or tolerance of pathogens has become one the global public crises. Finding new drug targets may open up a way infection control. Phenazine pyocyanin (PYO) is an important virulence factor produced by pathogen Pseudomonas aeruginosa. Here we show that multidrug efflux pump repressor, MexL, acts as transcriptional activator to enhance phenazines production via binding with conserved DNA motif within promoters biosynthesis genes. Moreover, PYO functions self-regulating ligand MexL for restricting its own and mexL knockout attenuates antibiotics P. Based on structure resolve, find two antimicrobials can interact reduce Our in vivo studies suggest combination using MexL-antagonists bacterial efficacy common be effective combat aeruginosa infection. microbial infections. In this work, authors present molecular basis dual-function regulator target control pathogenesis opportunistic

Language: Английский

Citations

1
Airway microbiome-immune crosstalk in chronic obstructive pulmonary disease DOI Creative Commons
Alex Kayongo, Nicole Robertson, Trishul Siddharthan

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 13

Published: Jan. 17, 2023

Chronic Obstructive Pulmonary Disease (COPD) has significantly contributed to global mortality, with three million deaths reported annually. This impact is expected increase over the next 40 years, approximately 5 people predicted succumb COPD-related Immune mechanisms driving disease progression have not been fully elucidated. Airway microbiota implicated. However, it still unclear how changes in airway microbiome drive persistent immune activation and consequent lung damage. Mechanisms mediating microbiome-immune crosstalk airways remain unclear. In this review, we examine dysbiosis mediates inflammation COPD. We give a detailed account of commensal bacteria interact mucosal innate adaptive system regulate responses healthy or diseased airways. Immune-phenotyping could advance COPD immunotherapeutics identify key open questions that future research must address further such translation.

Language: Английский

Citations

21
Bronchiectasis with Chronic Rhinosinusitis Is Associated with Eosinophilic Airway Inflammation and Is Distinct from Asthma DOI
Michal Shteinberg, James D. Chalmers, Jayanth Kumar Narayana

et al.

Annals of the American Thoracic Society, Journal Year: 2024, Volume and Issue: 21(5), P. 748 - 758

Published: Jan. 9, 2024

Bronchiectasis is an airway inflammatory disease that frequently associated with chronic rhinosinusitis (CRS). An eosinophilic endotype of bronchiectasis has recently been described, but detailed testing to differentiate from asthma not performed.

Language: Английский

Citations

8
Infection and the microbiome in bronchiectasis DOI Creative Commons
Micheál Mac Aogáin, Alison Dicker,

Pontus Mertsch

et al.

European Respiratory Review, Journal Year: 2024, Volume and Issue: 33(173), P. 240038 - 240038

Published: July 1, 2024

Bronchiectasis is marked by bronchial dilatation, recurrent infections and significant morbidity, underpinned a complex interplay between microbial dysbiosis immune dysregulation. The identification of distinct endophenotypes have refined our understanding its pathogenesis, including heterogeneous disease mechanisms that influence treatment prognosis responses. Next-generation sequencing (NGS) has revolutionised the way we view airway microbiology, allowing insights into “unculturable”. Understanding bronchiectasis microbiome through targeted amplicon and/or shotgun metagenomics provided key information on host immunity, central feature progression. rapid increase in translational clinical studies now provides scope for application precision medicine better efficacy interventions aimed at restoring balance modulating Holistic integration these driving an evolving paradigm shift bronchiectasis, which includes critical role unique with clinical, inflammatory, immunological metabolic factors. Here, review current state infection provide views future directions this field.

Language: Английский

Citations

7
Detailed Characterization of the Lung–Gut Microbiome Axis Reveals the Link between PD-L1 and the Microbiome in Non-Small-Cell Lung Cancer Patients DOI Open Access

Vytautas Ankudavičius,

Darja Nikitina, Rokas Lukoševičius

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(4), P. 2323 - 2323

Published: Feb. 15, 2024

Next-generation sequencing technologies have started a new era of respiratory tract research in recent years. Alterations the microbiome between healthy and malignant conditions been revealed. However, composition varies among studies, even similar medical conditions. Also, there is lack complete knowledge about lung–gut interactions lung cancer patients. The aim this study was to explore axis non-small-cell (NSCLC) patients associations microbiota clinical parameters (CRP, NLR, LPS, CD8, PD-L1). Lung tissue fecal samples were used for bacterial 16S rRNA sequencing. results revealed, first time, that richness tumor gradually decreased with an increase level PD-L1 expression (p < 0.05). An analysis β-diversity indicated significant positive correlation genera Romboutsia Alistipes both biopsies stool from NSCLC Survival showed higher their had prolonged overall survival (HR: 2.06, 95% CI: 1.025–4.17, p = 0.0426).

Language: Английский

Citations

5